The Global Brazil Injectable Drugs Market Growth Accelerated By Increasing Prevalence Of Chronic Diseases
![]() |
Brazil Injectable Drugs Market |
Injectable drugs are used for the direct administration of medicines into the body, which allows faster absorption of drugs and immediate systemic effects. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases has accelerated the demand for injectable drugs in Brazil. Brazil has a high incidence of cancer, with breast cancer and prostate cancer being the most common types of cancer. Furthermore, the change in lifestyle and increasing geriatric population are contributing to the rising disease burden.
The global
Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings is
estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to exhibit a
CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of chronic diseases is one of the key factors driving
the growth of the Brazil injectable drugs market. Chronic diseases require
long-term medication to manage the conditions effectively. Injectable drugs
allow for controlled and sustained release of medication into the body over an
extended period. This enhances treatment efficacy and compliance for chronic
diseases. Moreover, self-injectable drug delivery devices have gained
popularity as they allow patients to conveniently administer drugs at home. The
rising demand for self-administered injectable drugs and devices is expected to
push the market growth over the forecast period. Advancements in drug delivery
technologies are also helping expand the indications for injectable drugs and
facilitate development of novel drug formulations with reduced side effects.
Segment Analysis
The Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings is
dominated by the large volume injectable (LVI) sub-segment, accounting for
nearly 60% market share in 2023. LVIs are mainly administered in hospitals and
offer several advantages such as accurate and precise dosing, ease of
administration through intravenous injections, and quick onset of action. The
growing incidence of chronic diseases such as cancer, diabetes and
cardiovascular disorders which require long-term treatment through injectables
is driving the growth of this sub-segment.
Key Takeaways
The global Brazil
Injectable Drugs Market Demand for Hospitals & Ambulatory Settings
is expected to witness high growth over the forecast period from 2023 to 2030.
The global Brazil Injectable Drugs Market for Hospitals & Ambulatory
Settings is estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to
exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Regional analysis:
The Brazilian market is expected to dominate regionally, growing at a CAGR
of 5.2% during the forecast period. The high prevalence of chronic diseases and
improving healthcare infrastructure are fueling market growth in Brazil.
Improvements in hospital infrastructure and growing affordability are also
supporting the growth of ambulatory surgery centers in the country.
Key players: Key players operating in the Brazil Injectable Drugs Market for
Hospitals & Ambulatory Settings are Amcor Limited, Bemis Company, Sealed
Air Corporation, Berry Plastics Group, Inc., Mondi Group, Sonoco Products Co.,
Huhtamäki Oyj, Constantia Flexibles Gmbh, Ampac Holdings, Llc, Bischof +
KleinInternational, Wipak Group, AR Packaging, Goglio Group, Schur Flexibles,
Clondalkin Group, Flair Flexible Packaging Solution Cellpack Packaging, and
SÃ1⁄4dpack Verpackungen. These players are focusing on new product launches and
expanding their presence in the Brazilian market through collaborations with
local players.
Get more insights on this topic: https://www.newsstatix.com/brazil-injectable-drugs-market-analysis-scope/
Comments
Post a Comment